NCT06425003View on ClinicalTrials.gov

Study of [14C] ABBV-CLS-7262 in Healthy Male Volunteers Following Single Oral Dose Administration

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

May 21, 2024

Primary Completion Date

July 12, 2024

Study Completion Date

July 12, 2024

Conditions
Healthy Volunteer
Interventions
DRUG

[14C] ABBV-CLS-7262

Oral Solution

Trial Locations (1)

53704

Fortrea Clinical Research Unit Inc., Madison

Sponsors

Collaborators (1)

AbbVie
All Listed Sponsors
collaborator

AbbVie

INDUSTRY

lead

Calico Life Sciences LLC

INDUSTRY